Optimum management of type 2 diabetes - timely introduction, optimization and intensification of basal insulin

被引:6
作者
Dailey, G. [1 ]
机构
[1] Scripps Clin Torrey Pines, Dept Endocrinol & Diabet, San Diego, CA USA
关键词
hypoglycaemia; insulin glargine; insulin therapy; long-acting insulin; type; 2; diabetes;
D O I
10.1111/j.1463-1326.2008.00840.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The natural progression of type 2 diabetes mellitus (T2DM) requires continuing medical care, early insulin intensification and patient self-management education to reduce the risk of long-term complications, including microvascular and macrovascular complications. However, too few people are on insulin, and all too commonly have poor glycaemic control. This paradigm significantly increases the risk for long-term complications. It is becoming increasingly apparent that the early introduction of basal insulin, such as insulin glargine, is essential to provide clinically important improvements in glycaemic control. In this review, we discuss the rationale for the earlier insulinization in T2DM in order to reach and maintain treatment targets and to provide further support for the recent American Diabetes Association and European Association for the Study of Diabetes consensus statement.
引用
收藏
页码:5 / 13
页数:9
相关论文
共 60 条
[1]  
ALBERTI G, 1998, EXP CLIN ENDOCRINOL, V107, P390
[2]  
Am Diabetes Assoc, 2006, DIABETES CARE, V29, pS4
[3]  
[Anonymous], 1995, Diabetes, V44, P1249
[4]  
[Anonymous], 2007, DIABETES CARE, DOI DOI 10.2337/DC07-S004
[5]   A review of basal insulins [J].
Barnett, AH .
DIABETIC MEDICINE, 2003, 20 (11) :873-885
[6]   Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c [J].
Bastyr, EJ ;
Stuart, CA ;
Brodows, RG ;
Schwartz, S ;
Graf, CJ ;
Zagar, A ;
Robertson, KE .
DIABETES CARE, 2000, 23 (09) :1236-1241
[7]  
Benedetti MM, 2003, HORM METAB RES, V35, P189
[8]   Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes [J].
Bott, S ;
Tusek, C ;
Jacobsen, LV ;
Endahl, L ;
Draeger, E ;
Kapitza, C ;
Heise, T .
DIABETIC MEDICINE, 2006, 23 (05) :522-528
[9]   Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine [J].
Bradley, C. ;
Gilbride, C. J. B. .
DIABETES OBESITY & METABOLISM, 2008, 10 :50-65
[10]   Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial [J].
Bretzel, Reinhard G. ;
Nuber, Ulrike ;
Landgraf, Wolfgang ;
Owens, David R. ;
Bradley, Clare ;
Linn, Thomas .
LANCET, 2008, 371 (9618) :1073-1084